ReviewFrontiers in pharmacology2014
Label-free drug discovery.
Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Harnessing AI to fuse phenotypic signatures for drug target identification: progress in computational modeling.Briefings in bioinformatics · 2026Review
- Drug Repurposing to Inhibit Oncostatin M in Crohn's Disease.Molecules (Basel, Switzerland) · 2025Article
- Label-free live cell recognition and tracking for biological discoveries and translational applications.Npj imaging · 2024Review
- Review
- Label-free biomolecular and cellular methods in small molecule epigallocatechin-gallate research.Heliyon · 2024Review
- Sensing of Antibiotic-Bacteria Interactions.Antibiotics (Basel, Switzerland) · 2023Review
- Label-Free Optical Sensing and Medical Grade Resins: An Advanced Approach to Investigate Cell-Material Interaction and Biocompatibility.Pharmaceutics · 2023Article
- Proteomics reveals that cell density could affect the efficacy of drug treatment.Biochemistry and biophysics reports · 2023Article
- The Purinosome: A Case Study for a Mammalian Metabolon.Annual review of biochemistry · 2022Review
- Monitoring the effects of chemical stimuli on live cells with metasurface-enhanced infrared reflection spectroscopy.Lab on a chip · 2021Article
- Label-Free Investigations on the G Protein Dependent Signaling Pathways of Histamine Receptors.International journal of molecular sciences · 2021Article
- Relevant Features of Polypharmacologic Human-Target Antimicrobials Discovered by Machine-Learning Techniques.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Gomisin M2 Inhibits Mast Cell-Mediated Allergic InflammationFrontiers in pharmacology · 2019Article
- Identification of radiation-induced EndMT inhibitors through cell-based phenomic screening.FEBS open bio · 2019Article
- Discovery of novel antagonists on βNaunyn-Schmiedeberg's archives of pharmacology · 2018Article
- Article
- Label-free toxicology screening of primary human mesenchymal cells and iPS-derived neurons.PloS one · 2018Article
- Elaeocarpusin Inhibits Mast Cell-Mediated Allergic Inflammation.Frontiers in pharmacology · 2018Article
- A New View into the Regulation of Purine Metabolism: The Purinosome.Trends in biochemical sciences · 2017Review
- Label-free fingerprinting of tumor cells in bulk flow using inline digital holographic microscopy.Biomedical optics express · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current drug discovery is dominated by label-dependent molecular approaches, which screen drugs in the context of a predefined and target-based hypothesis in vitro. Given that target-based discovery has not transformed the industry, phenotypic screen that identifies drugs based on a specific phenotype of cells, tissues, or animals has gained renewed interest. However, owing to the intrinsic complexity in drug-target interactions, there is often a significant gap between the phenotype screened and the ultimate molecular mechanism of action sought. This paper presents a label-free strategy for early drug discovery. This strategy combines label-free cell phenotypic profiling with computational approaches, and holds promise to bridge the gap by offering a kinetic and holistic representation of the functional consequences of drugs in disease relevant cells that is amenable to mechanistic deconvolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.